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Abstract
Down syndrome (DS), with trisomy of chromosome 21 (HSA21), is the commonest human
aneuploidy. Pre-leukemic myeloproliferative changes in DS foetal livers precede the acqui-
sition ofGATA1mutations, transient myeloproliferative disorder (DS-TMD) and acute mega-
karyocytic leukemia (DS-AMKL). Trisomy of the Erg gene is required for myeloproliferation
in the Ts(1716)65Dn DSmouse model. We demonstrate here that genetic changes specifi-
cally attributable to trisomy of Erg lead to lineage priming of primitive and early multipotential
progenitor cells in Ts(1716)65Dn mice, excess megakaryocyte-erythroid progenitors, and
malignant myeloproliferation. Gene expression changes dependent on trisomy of Erg in Ts
(1716)65Dn multilineage progenitor cells were correlated with those associated with trisomy
of HSA21 in human DS hematopoietic stem and primitive progenitor cells. These data sug-
gest a role for ERG as a regulator of hematopoietic lineage potential, and that trisomy of
ERG in the context of DS foetal liver hemopoiesis drives the pre-leukemic changes that pre-
dispose to subsequent DS-TMD and DS-AMKL.
Author Summary
An excess number of genes in trisomy on human chromosome 21 leads to the develop-
ment of specific diseases in human Down syndrome. An excess copy of the gene, ERG, an
ETS family transcription factor, has been implicated in abnormal blood system develop-
ment in Down syndrome. In this study we show how trisomy of Erg in a murine Down
syndrome model perturbs hematopoietic progenitor cells in a manner similar to that ob-
served in human Down syndrome by inducing gene expression changes and lineage prim-
ing in early multi-potential progenitors. We show that the gene expression signature
specifically attributable to trisomy of Erg in the murine model is strongly correlated with
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gene expression changes in human Down syndrome hematopoietic cells. The data suggest
that Erg is an important regulator of megakaryocyte-erythroid lineage specification in
multipotential hematopoietic cells and that trisomy of Erg in the context of DS prediposes
to a transient myeloproliferative disorder and acute megakaryocyte leukaemia in a multi-
step model of leukemogenesis.
Introduction
Down syndrome (DS) is the commonest human aneuploidy [1]. DS infants with trisomy of
human chromosome 21 (HSA21) are uniquely predisposed to a transient myeloproliferative
disorder (DS-TMD) and acute megakaryocytic leukemia (DS-AMKL) [2]. DS-TMD, usually
characterised by the presence of peripheral immature myeloblasts/megakaryoblasts and the
variable involvement of other organs, is restricted to the neonatal period, spontaneously re-
gresses and is the result of genetic co-operation between trisomy of HSA21 gene(s) with an ac-
quired somatic mutation in GATA1 in virtually all cases [3]. However, up to 30% of children
will subsequently develop DS-AMKL, a malignancy clonally related to the preceding DS-TMD.
Candidate gene analysis and genome-wide exome sequencing have identified somatic muta-
tions and deletions implicated in the progression of DS-TMD to DS-AMKL, in genes including
JAK1, JAK2, JAK3, FLT3, TP53, TRIB1,MPL, EZH2, APC, PARK-2, PACRG, EXT1, DLEC1
and SMC3, and further suggested that GATA-1mutations alone in the context of HSA21 triso-
my were sufficient for development of DS-TMD [4–12].
Preceding acquisition of GATA1mutations, human DS foetal livers exhibit perturbed hema-
topoiesis. Increased numbers and clonogenicity of hematopoietic stem (HSC) and progenitor
cells, increased frequency of bi-potential megakaryocyte-erythroid progenitors, and reduced
numbers of granulocyte-macrophage-committed progenitor cells have been described [13–15].
This perturbation must be attributed to a specific trisomic gene or genes on HSA21 that drive
the pre-leukemic DS phenotype from which DS-AMKL and DS-TMD subsequently arise. Mu-
rine DS models with germline transmissible segmental trisomies of human or murine ortholo-
gues of HSA21 genes have allowed genetic analyses of the contributions of genes within the DS
critical interval to specific DS phenotypes [16–19]. A well studied model is the Ts(1716)65Dn
mouse, which is trisomic for orthologs of ~104 human chromosome 21 genes [17]. Ts(1716)
65Dn mice display progressive myeloproliferation chracterised by thrombocytosis, megakaryo-
cyte hyperplasia, dysplastic megakaryocytic morphology and myelofibrosis. Similarly, blasts
with erythro-megakaryocytic features and myelofibrosis are commonly observed in organs af-
fected by DS-TMD/AMKL, while DS foetal livers show increased numbers of bipotential mega-
karyocyte-erythroid progenitors with increased clonogenicity and megakaryocyte/erythroid
potential as well as megakaryocytosis [13–15].
We previously implicated the ETS family transcription factor ERG as a critical HSA21 gene
in DS hematopoietic disease by demonstrating that specific reversion of Erg gene dosage to
functional disomy, while the other ~103 orthologs remained trisomic, abrogated the myelo-
megakaryocytic proliferation in Ts(1716)65Dn mice [20]. Erg has previously been shown to be
essential for normal hematopoietic stem cell function [21–23]. Moreover, Erg deregulation can
cause erythro-megakaryocytic leukemia in mice [24,25], and is implicated in acute myeloid
and lymphoid malignancy in humans. In t(16;21) AML that carry the ERG/TLS-FUS fusion,
complex karyotype AML with amplification of 21q, normal karyotype adult AML,MLL-
rearranged paediatric AML and in T-ALL, high levels of ERG expression correlate with poor
prognosis [26–29].
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The detailed mechanisms by which Erg contributes in trisomy to myeloproliferation in Ts
(1716)65Dn mice, and whether molecular changes specifically driven by three copies of Erg in
this model reflect those associated with human DS, remained to be elucidated. To address
these questions, we detailed hematopoietic progenitor perturbations associated with malignant
myeloproliferation in 4 month-old Ts(1716)65Dn mice, the youngest age at which myeloid pro-
genitor abnormalities have been observed [30]. We then performed transcriptome analysis of
hematopoieitic stem cell (HSC) and myeloid progenitor cell-enriched populations from the
bone marrow of Ts(1716)65Dn mice to define the relevant biological and genetic changes by
which trisomy predisposes to development of myeloproliferation in this DS model [20]. Tran-
scriptome changes in multipotential progenitor cells that were attributed specifically to trisomy
of Erg in the Ts(1716)65Dn mouse were then compared to expression changes due to trisomy
of chromosome 21 (HSA21) in human DS CD34+CD38- hematopoietic cells [31] to explore
the role of ERG gene dosage in human disease.
Results
Trisomy of Erg in Ts(1716)65Dn mice drives changes to erythro-
megakaryocytic progenitor cells similar to those in human DS
The stem-cell enriched lineage-negative cKit+Sca1+ (LSK) population has been previously
shown to be expanded in trisomic Ts(1716)65Dn DS mice [20,30]. This population, which
functionally resembles the expanded stem cell-enriched compartment in human DS foetal liv-
ers [15], was corrected to wild-type levels in Ts(1716)65Dn mice when Erg was specifically re-
duced from trisomy to functional disomy [20]. Moreover, it has been observed that, in addition
to changes in stem cell numbers, bipotential erythroid-megakaryocyte progenitor populations
are also perturbed in human DS [15]. We therefore sought to define the effects of trisomy on
specific murine hematopoietic progenitor cells in the Ts(1716)65Dn DS model. Ts(1716)65Dn
trisomic mice were crossed to mice carrying the non-functional ErgMld2 allele as previously de-
scribed [20]. The four resulting genotypes: mice trisomic for ~104 orthologs of human chro-
mosome 21 genes including Erg (Ts65Dn/Erg+/+/+), mice disomic for functional Erg and
trisomic for the remaining ~103 genes in the trisomic segment (Ts65Dn/Erg+/+/Mld2), euploid
mice (Erg+/+) and disomic mice with one functional Erg allele (Erg+/Mld2), were analysed at 4
months of age for abnormalities in common myeloid progenitors (CMP), granulo-monocytic
progenitors (GMP), and megakaryocyte-erythroid progenitors (MEP) as previously defined
[32]. Consistent with previous data [30], increased numbers of GMPs and a deficit of MEPs
were evident in Ts65Dn/Erg+/+/+ mice (Fig 1A). These abnormalities were corrected in
Ts65Dn/Erg+/+/Mld2 mice (Fig 1A), suggesting that trisomy of Erg is specifically associated with
perturbations of myeloid progenitors of several hematopoietic lineages in the Ts(1716)65Dn
DS model.
Myeloid progenitors in Ts65Dn/Erg+/+/+ mice were then examined in greater detail, with
particular emphasis on the recently described series of progressively maturing BEMP,
CD150+CD9hi and CD150+FcγR+ bipotential erythroid-megakaryocyte progenitors [33,34], as
well as pre-granulocyte macrophage (PreGM), granulocyte-macrophage (GMP), pre-colony
forming unit erythroid (PreCFU-E) and colony forming unit erythroid (CFU-E) populations
[33,35], defined in S1 Table (Fig 1B and 1C). Trisomic Ts65Dn/Erg+/+/+ mice contained in-
creased numbers of GMP and CD150+CD9hi bipotential progenitor cells, and these were nor-
malised in number when Erg was reduced to functional disomy in Ts65Dn/Erg+/+/Mld2 mice.
Conversely, the numbers of GMPs and bipotential megakaryocyte-erythroid progenitor popu-
lations (BEMP, CD150+CD9hi, CD150+FcγR+) were reduced in Erg+/Mld2 mice haploinsuffi-
cient for functional Erg. Trisomic Ts65Dn/Erg+/+/+ mice were noted to have significantly fewer
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CFU-E, an anomaly that was not evident in Ts65Dn/Erg+/+/Mld2 mice and Erg+/Mld2 mice had
an expanded population of these late erythroid progenitors, supporting previous data that sug-
gested Erg normally restrains terminal erythroid differentiation [22,24,25]. Consistent with the
immunophenotypic analyses, in clonogenic assays, Ts65Dn/Erg+/+/+ bone marrow demonstrat-
ed stimuli-specific increases in the numbers of granulocyte, macrophage and megakaryocyte
colony-forming units (CFU). This myeloproliferation was moderated in Ts65Dn/Erg+/+/Mld2
mice (Table 1). Together, these data support a role for Erg in regulation of multiple hematopoi-
etic lineages. The bias toward megakaryocyte and away from erythroid progenitor formation
Fig 1. Perturbation of hematopoietic progenitors in the Ts(1716)65Dn DSmousemodel due to trisomy
of Erg. A. Relative proportions of GMP, CMP and MEP progenitor subsets within the Lineage-cKit+Sca1-
bone marrow fraction of Erg+/Mld2 (n = 12; male = 9, female = 3), Erg+/+ (n = 12; male = 4, female = 8),
Ts65Dn/Erg+/+/Mld2 (n = 10; male = 4, female = 6) and Ts65Dn/Erg+/+/+mice (n = 11; male = 7, female = 4).
* P < 0.05 compared to Erg+/+, ** P < 0.05 compared to Ts65Dn/Erg+/+/Mld2 by Student's two-tailed t-test.B &
C. Analysis of hematopoietic progenitor cells including bipotential erythroid-megakaryocyte progenitor
populations as previously defined [33,34]. Representative flow cytometry profiles and gating strategies for
analysis of cell populations from bone marrow of Erg+/Mld2 (n = 13; male = 4, female = 9), Erg+/+ (n = 10;
male = 7, female = 3), Ts65Dn/Erg+/+/Mld2 (n = 5; male = 4, female = 1) and Ts65Dn/Erg+/+/+ (n = 7; male = 7)
mice are shown. See S1 Table for immunophenotype definitions. (B) The mean number of each population is
shown as the percentage of viable bone marrow cells or proportion of Lin-cKit+Sca1-CD150+ cells ± standard
deviation. * P < 0.05 compared to Erg+/+, ** P < 0.05 compared to Ts65Dn/Erg+/+/Mld2. (C) The relative
increase or decrease of each progenitor populations compared to wild-type (Erg+/+) with mean and standard
deviations shown, * P < 0.05 compared to Erg+/+.
doi:10.1371/journal.pgen.1005211.g001
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that was specifically attributable to trisomy of Erg in Ts(1716)65Dn mice resembles progenitor
abnormalities observed in pre-leukemic human DS foetal livers prior to acquisition of GATA1
mutations, although human DS foetal livers exhibit reduced numbers of GMP, in contrast to
the mouse model [15].
Trisomy of Erg drives gene expression changes in multipotential
progenitor cell populations
We undertook gene expression profiling of prospectively isolated LSK, CMP, GMP and MEP
populations from Ts65Dn/Erg+/+/+, Ts65Dn/Erg+/+/Mld2, Erg+/+ and Erg+/Mld2 mice. Gene ex-
pression changes within each cell population that were attributable to changes in functional
Erg gene dosage were determined by specific pair-wise comparisons using linear modeling and
empirical Bayes moderated t-statistics [36]. Changes due to full trisomy of all ~104 syntenic
genes were inferred from comparison of Ts65Dn/Erg+/+/+ versus Erg+/+ mice, trisomy-induced
changes specifically attributable to trisomy of Erg were evident from comparison of Ts65Dn/
Erg+/+/+ versus Ts65Dn/Erg+/+/Mld2 (effects specific to Erg trisomy), changes due to trisomy
with two copies of functional Erg (effects due to non-Erg gene trisomy) emerged from compari-
son of Ts65Dn/Erg+/+/Mld2 versus Erg+/+, and changes due to Erg haplo-insufficiency from com-
parison of Erg+/Mld2 versus Erg+/+.
We initially explored the expression in LSK, CMP, GMP and MEP cells of the ~104 HSA21
orthologs present in trisomy in Ts65Dn/Erg+/+/+ mice compared with their expression in
Erg+/+ cells. Increased expression of these genes in trisomc cells varied and was also dependent
on the specific hematopoietic cell type examined (Fig 2A). At a false discovery rate of 5% across
the entire transcriptome, Son, Usp16, Cyrzl1, Gart, Cct8 were upregulated in LSK cells, Sfrs15,
Ifngr2, Ifnar2, Gart, Atp5j in CMPs, and Gart, Chaf1b,Hlcs, Ttc3 in GMPs of Ts(1716)65Dn
mice (Fig 2A and S2 Table).
The greatest number of gene expression changes due to full trisomy (Ts65Dn/Erg+/+/+ versus
Erg+/+) or specifically to Erg trisomy (Ts65Dn/Erg+/+/+ versus Ts65Dn/Erg+/+/Mld2) occurred in
the LSK compartment, while gene expression changes attributable to trisomy of non-Erg genes
in the interval (Ts65Dn/Erg+/+/Mld2 versus Erg+/+) were fewer and occurred principally in MEP
and GMP populations (Table 2). In addition, in LSK cells there was a strong degree of overlap
in differentially expressed genes due to full trisomy and specifically due to trisomy of Erg, both
in up- and down-regulated genes (Fig 2B, 2C and 2D).
Given the correlation of gene expression changes induced by full trisomy with those associ-
ated specifically with trisomy of Erg, a Genuine Association Analysis (GENAS) was undertak-
en. GENAS is a relatively new statistical technique that estimates the biological correlation
between two differential expression profiles, correcting for any technical correlation and for
the statistical uncertainty with which the fold changes are estimated [37,38]. Unlike the initial
analysis in Fig 2B, GENAS does not depend on a significance cut-off and instead calculates an
overall correlation using all expressed genes. In confirmation of the initial analyses, there was a
very high degree of biological correlation in LSK cells between gene expression changes caused
by trisomy of the full HSA21 syntenic segment and those associated specifically with trisomy of
Erg. The strongest correlation between expression changes resulting from full trisomy and
those due to trisomy of non-Erg genes occurred within MEP cells (Fig 3). Notably, the degree
of biological correlation between gene expression changes attributable specifically to Erg triso-
my and those due to trisomy of non-Erg genes was weak in all cell types analysed, suggesting
gene expression changes induced specifically by trisomy of Erg were distinct from the com-
bined effect of other genes within the Ts(1716)65Dn trisomic segment.
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Together, these findings establish that in hematopoietic progenitor cells, Erg is the dominant
influence within the Ts(1716)65Dn trisomic interval, three copies of which specifically drives
gene expression changes that are evident primarily within multipotential hematopoietic pro-
genitor populations rather than more lineage-restricted progenitors.
Trisomy of Erg induces lineage priming in multipotential progenitor cells
We next sought to understand how gene expression changes induced specifically by trisomy of
Erg could lead to perturbations of hematopoietic progenitors and the myeloproliferative phe-
notype observed in Ts(1716)65Dn mice. To do this, we undertook an expression signature anal-
ysis of the expression changes in the Ts65Dn/Erg+/+/+ versus Ts65Dn/Erg+/+/Mld2 cells using
curated gene sets from the Molecular Signatures database (MSigDB version 2.5) and pathway
Fig 2. Comparison of gene expression changes due to full trisomy and specifically to trisomy of Erg
in Ts(1716)65Dn LSKs. A. Differential expression of murine orthologs of HSA21 trisomic genes in Ts65
(1716)Dn hematopoietic cells [51]. Heatmap diagram of log2 fold expression changes for genes with
detectable expression in microarray data from the LSK, CMP, GMP and MEP cells for comparison between
Ts65DnErg+/+/+ and Erg+/+ genotypes. Trisomic genes with significantly upregulated gene expression in Ts65
(1716)Dn cells using a false discovery rate of 5% are indicated in red with an asterix.B. Barcode plot
demonstrating distribution of differentially expressed genes due specifically to trisomy of Erg (pairwise
comparison Ts65Dn/Erg+/+/+ versus Ts65Dn/Erg+/+/Mld2; red bars: upregulated genes; blue bars:
downregulated genes) relative to gene expression changes due to overall trisomy (pairwise comparison
Ts65Dn/Erg+/+/+ versus Erg+/+) in LSK cells.C. Venn diagram of differentially regulated genes in LSK cells
due to the effect of overall trisomy (Ts65Dn/Erg+/+/+ versus Erg+/+), trisomy of Erg (Ts65Dn/Erg+/+/+ versus
Ts65Dn/Erg+/+/Mld2) and non-Erg trisomy (Ts65Dn/Erg+/+/Mld2 versus Erg+/+). Intersect of differentially
expressed genes by t-stastistic using an FDR of < 5%; (red) intersect of differentially expressed genes due to
trisomy and Erg trisomy; (yellow) non-intersecting differentially expressed genes due to trisomy; (blue) non
intersecting differentially expressed genes due to trisomy of Erg. D. Dot plot of differentially expressed genes
in LSK cells by t-statistic comparing expression differences resulting from overall trisomy (Ts65Dn/Erg+/+/+
versus Erg+/+) to those specifically attributable to Erg trisomy (Ts65Dn/Erg+/+/+ versus Ts65Dn/Erg+/+/Mld2, left
panel) and Erg trisomy compared to expression changes specific for non-Erg genes in trisomy (Ts65Dn/
Erg+/+/Mld2 versus Erg+/+, right panel). Genes identified in the Venn diagram (Fig 2C) are shown using the
same color scheme suggesting a high degree of correlation between differentially expressed genes due to
trisomy and Erg trisomy in LSK cells.
doi:10.1371/journal.pgen.1005211.g002
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gene sets defined by the BioCarta, KEGG and Reactome databases. A ROAST test was con-
ducted for each signature gene set. ROAST is a gene set test suitable for small samples and line-
ar models that accounts for inter-gene correlation [38,39]. ROAST evaluates whether the
overall expression signature defined by a gene set is up- or down-regulated within a specific
comparison. This analysis found that expression signatures associated with progenitor cells of
Table 2. Differential gene expression due to full trisomy, attributable specifically to Erg trisomy, and trisomy of non-Erg genes.
LSK CMP GMP MEP
Full trisomy Ts65Dn/Erg+/+/+ versus Erg+/+ UP 147 35 29 90
NS 22068 22318 22310 22212
DOWN 159 21 35 72
Erg trisomy speciﬁcally Ts65Dn/Erg+/+/+ versus Ts65Dn/Erg+/+/Mld2 UP 217 2 2 4
NS 21896 22369 22369 22364
DOWN 261 3 3 6
Non-Erg gene trisomy Ts65Dn/ErgMld2/+/+ versus Erg+/+ UP 2 1 19 27
NS 22370 22370 22335 22323
DOWN 2 3 20 24
Differential gene expression with the number of up-regulated and down-regulated probes (False discovery rate (FDR) of 0.05, NS = not signiﬁcant), as a
consequence of full trisomy (pairwise comparison Ts65Dn/Erg+/+/+ versus Erg+/+), trisomy of Erg (Ts65Dn/Erg+/+/+ versus Ts65Dn/Erg+/+/Mld2) and non-Erg
gene trisomy (Ts65Dn/Erg+/+/Mld2 versus Erg+/+) in LSK, CMP, GMP and MEP hematopoietic cells (see [20], Fig 1A and S2 Table). Three biological
replicates per cell type per genotype were obtained using pooled RNA derived from 2–4 mice (including male and female) per genotype per replicate, for a
total of 48 arrays.
doi:10.1371/journal.pgen.1005211.t002
Fig 3. Biological correlation of gene expression changes using gene association analysis. Scatter
plots by log2 fold gene expression changes in LSK, CMP, GMP and MEP cells comparing: top panel,
changes due to full trisomy (Ts65Dn/Erg+/+/+ versus Erg+/+) with those specific for trisomy of Erg (Ts65Dn/
Erg+/+/+ vs Ts65Dn/Erg+/+/Mld2); middle panel, expression changes due to full trisomy with those attributable
to non-Erg genes in trisomy (Ts65Dn/Erg+/+/Mld2 versus Erg+/+); and lower panel changes attributable to Erg
trisomy with those non-Erg genes in trisomy. Green ellipses indicate the strength of biological correlation
(ρbiol) and blue ellipses show technical correlation (ρtech) as estimated by GENAS.
doi:10.1371/journal.pgen.1005211.g003
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specific hematopoietic lineages, including granulocyte-monocyte progenitors, megakaryocytes,
platelets and platelet processes, were significantly upregulated in the Ts65Dn/Erg+/+/+ cells
(ROAST P-value< 0.05, S3 Table). By contrast, signatures associated with myeloproliferation
were not significantly enriched in Ts65Dn/Erg+/+/+ versus Ts65Dn/Erg+/+/Mld2 LSK cells.
Given these findings, and as we had observed perturbations in specific hematopoietic pro-
genitor populations in Ts65Dn/Erg+/+/+ bone marrow (Fig 1 and Table 1), we examined wheth-
er the gene expression changes specific to trisomy of Erg in Ts(1716)65Dn mice could be
interpreted in terms of cell lineage priming. We generated gene expression signatures that de-
fine specific cell populations: LSK, GMP and their precursors (Pre-GM Flt3+, Pre-GM Flt3-),
megakaryocytes and their progenitors (BEMP, CD150+ CD9hi, CD150+ FcγR+), and CFU-E
and pre-CFU-E. An expression signature was defined for each cell population by compiling the
significantly up-regulated genes in that cell type compared to the average of all the other popu-
lations, together with the magnitude of the up-regulation for each gene as measured by the
moderated t-statistic (S4 Table). ROAST tests were then conducted, with genes weighted by
their magnitude of change, to determine whether these signatures were associated with the
gene expression changes due to full trisomy (Ts65Dn/Erg+/+/+ versus Erg+/+), the specific effects
of Erg trisomy (Ts65Dn/Erg+/+/+ versus Ts65Dn/Erg+/+/Mld2), the effects of trisomy of non-Erg
genes (Ts65Dn/Erg+/+/Mld2 versus Erg+/+) and Erg haploinsufficiency (Ts65Dn/Erg+/+ versus
Erg+/Mld2) in LSK, CMP, GMP and MEP populations.
Signatures of more committed progenitors, particularly multipotential PreGM Flt3- cells,
granulo-monocytic progenitors (PreGM Flt3+ and GMP), bipotential megakaryocyte-erythroid
progenitors (CD150+CD9hi and CD150+FcγR+) and megakaryocytes, were enriched in the
gene expression changes due to trisomy of Erg in LSK cells, and this was also evident in CMPs
by this comparison (Fig 4). In LSK cells, this was accompanied by downregulation of the nor-
mal LSK gene signature indicative of a more differentiated profile (Fig 4). In contrast, erythroid
progenitor signatures (PreCFU-E and CFU-E) were enriched in the gene expression changes
caused by haploinsufficiency of functional Erg in LSK and CMP cells (Fig 4). Strikingly, these
genetic changes attributable specifically to trisomy of Erg in Ts(1716)65Dn LSKs and CMPs
were concordant with the increased numbers of GMP and megakaryocyte-committed cells and
fewer erythroid progenitors that were evident in Ts65Dn/Erg+/+/+ but not Ts65Dn/Erg+/Mld2+
mice, as well as the relative enrichment of erythroid progenitors in mice with Erg haploinsuffi-
ciency (Fig 1).
Finally, we investigated the expression of genes implicated by somatic mutations and dele-
tions in the progression of DS-TMD to DS-AMKL. Of these genes, expression of the murine
orthologues for JAK1, JAK2, JAK3, FLT3, TP53, TRIB1,MPL, EZH2, APC, EXT1 and SMC3
was detected in the microarray data from LSK, CMP, GMP or MEP cells. While modest differ-
ences were evident in expression of some of these genes in comparisons between cells from
Ts65Dn/Erg+/+/+ and Erg+/+ mice, differential expression of these genes did not reach statistical
significance (S1 Fig and S2 Table).
Thus, the data support a model in which gene expression changes attributable specifically to
trisomy of Erg in Ts(1716)65Dn mice occur primarily in multipotential hematopoietic cells
with priming for specific hematopoietic progenitor lineages leading to myeloid progenitor per-
turbation, myeloproliferative changes and megakaryocytosis.
Erg-trisomy gene signatures in Ts(1716)65Dn LSKs correlate with gene
expression changes in human DS CD34+CD38- bone marrow cells
Transcriptome profiling of human DS Lin-CD45+CD34+CD38- bone marrow cells enriched
for HSCs and multipoential hematopoietic progenitors that had been previously combined
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with transcriptomes of DS neurospheres derived from foetal cortical precursors, demonstrated
differences in gene expression when compared to diploid controls [31]. We sought to establish
if DS Lin-CD45+CD34+CD38- bone marrow cells specifically demonstrated gene expression
changes associated with trisomy of HSA21 when compared to diploid controls, and if these
were related to differential gene expression due to Erg trisomy in LSKs in the Ts(1716)65Dn DS
model. From the published data [31], we derived gene expression signatures for human DS
HSC and multipotential progenitor cells that were induced by trisomy of HSA21 (S5 Table).
We then used ROAST to compare these human DS gene signatures to gene expression changes
induced by full trisomy in Ts(1716)65Dn LSK cells, as well as those specific to trisomy of Erg
and those due to trisomy of non-Erg genes (Fig 5). The human DS gene signatures were strong-
ly and significantly correlated with gene expression changes due specifically to Erg trisomy in
Ts(1716)65Dn LSK cells, but not with those attributable to trisomy of non-Erg genes (Fig 5A).
The complementary analysis was then undertaken. ROAST tests showed that gene expression
changes specifically induced by trisomy of Erg in Ts(1716)65Dn LSK cells significantly correlat-
ed with gene expression changes due to trisomy of HSA21 in human DS Lin-CD34+CD38- cells
(Fig 5B). This genetic data supports the role of ERG as a key gene on HSA21 which in trisomy,
drives the hematopoietic phenotype in human DS.
Discussion
We show here, in comparisons between Ts65Dn/Erg+/+/+ mice, in which a ~104-gene interval
syntenic to HSA21 is present in trisomy, and their Ts65Dn/Erg+/+/Mld2 counterparts, in which
Fig 4. Hematopoietic lineage specific gene signatures induced by Erg trisomy in Ts(1716)65Dn LSK
and CMP cells. Enrichment of LSK, myeloid progenitor and megakaryocyte gene signatures in the gene
expression changes due to complete trisomy (defined by the comparison of gene expression in Ts65Dn/
Erg+/+/+ versus Erg+/+ cells), the gene expression changes attributable specifically to Erg trisomy (Ts65Dn/
Erg+/+/+ versus Ts65Dn/Erg+/+/Mld2), those due to trisomy of non-Erg genes (Ts65Dn/Erg+/+/Mld2 versus
Erg+/+); and those due to Erg haploinsufficiency (Ts65Dn/Erg+/+ vs Ts65Dn/Erg+/Mld2) in LSK and CMP
populations. Heatmap by Pearson correlation of Z score equivalents derived from ROAST P-values using
progenitor gene signatures weighted by moderated t-statistic is shown (see S4 Table, Materials and
Methods). Yellow indicates upregulation of cell type-specific gene signatures (positive Z score equivalent)
and blue downregulation of these signatures (negative Z score equivalent). A higher absolute Z score
equivalent value represents more significant enrichment.
doi:10.1371/journal.pgen.1005211.g004
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the Erg gene within this interval is specifically reduced to functional disomy, that trisomy of
Erg is specifically required for the characteristic perturbations in specific hematopoietic pro-
genitor cell populations in the Ts(1716)65Dn DS model. Unlike transgenic and retroviral mod-
els of induced Erg expression, the use of the non-functional ErgMld2 allele in this model allows
accurate characterisation of effects of functional Erg gene dosage while expression is endoge-
nously regulated. The hematopoietic changes in Ts(1716)65Dn mice reflected the pre-leukemic
changes observed in human DS foetal livers prior to acquisition of GATA-1 or other somatic
mutations. While these analyses do not exclude contribution from other genes within the
trisomic interval, they clearly establish that three copies of Erg is specifically required to drive
Fig 5. Human DS Lin-CD34+CD38- HSPC gene expression changes correlate with changes due to
trisomy of Erg in Ts(1716)65Dn LSK cells. A. Barcode plots of upregulated genes in human DS
Lin-CD34+CD38- stem and progenitor cells (HSPC) relative to diploid HSPCs using a FDR of 0.05, 0.10, 0.15
and 0.20 (see S5 Table) compared to gene expression changes in Ts(1716)65Dn LSK cells due to full trisomy
defined by the comparison of gene expression in Ts65Dn/Erg+/+/+ versus Erg+/+ cells, (left panels), changes
attributable specifically to Erg trisomy (Ts65Dn/Erg+/+/+ versus Ts65Dn/Erg+/+/Mld2, middle panels), and those
due to trisomy of non-Erg genes (Ts65Dn/Erg+/+/Mld2 versus Erg+/+, right panels). Human DS HSPC genes
(black bars) are upregulated in Ts(1716)65Dn LSK gene expression changes attributable specifically to
trisomy of Erg (middle panels) but not due to trisomy of non-Erg genes (right panels). Rotation gene set test
ROAST P-values shown.B. Barcode plot showing correlation between gene expression changes in Ts(1716)
65Dn LSK cells due to Erg trisomy (from comparison of Ts65Dn/Erg+/+/+ versus Ts65Dn/Erg+/+/Mld2) with
gene expression changes in human DS HSPCs relative to diploid cells. Horizontal axis shows moderated t-
statistic values for the human DS HSPC versus diploid HSPCs comparison. Red bars show upregulated
genes and blue bars downregulated genes resulting specifically from Erg trisomy in Ts(1716)65Dn LSK cells
(FDR < 0.05, S2 Table). Red and blue worms show relative enrichment of up and downregulated genes
respectively (ROAST P-value = 0.029 for upregulated genes).
doi:10.1371/journal.pgen.1005211.g005
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transcriptome changes in HSCs and early multipotential progenitors in Ts(1716)65Dn mice.
Moreover, the data provide a mechanism by which deregulation of Erg leads to perturbation of
myeloid progenitor populations, myeloproliferation and megakaryocytosis in trisomy. Our
findings show that perturbation of functional Erg gene dose by trisomy or by haploinsuffi-
ciency, is associated with lineage specific gene expression changes and "lineage priming" of
multipotential hematopoietic progenitor cells. Notably, the effects specific to trisomy of Erg on
gene expression and progenitor cell alterations in Ts(1716)65Dn mice were strongly reflected in
Erg+/Mld2 mice, but in the opposite direction. Finally, we demonstrate that the gene signature
specifically associated with trisomy of Erg in Ts(1716)65Dn LSK cells is directly related to gene
expression changes in human DS Lin-CD34+CD38- cells enriched for HSCs and early multipo-
tential progenitors. These data support a key role for ERG as a critical gene in trisomy of
HSA21 that drives hematopoietic changes in human DS.
Previous analyses established that Erg is an important regulator of HSC self-renewal after
establishment of definitive hematopoiesis in the embryo [23] and in emergency hematopoiesis
in adult HSCs [21,22]. The data presented here imply additional roles for Erg for lineage prim-
ing in early multipotential hematopoietic cells which affects subsequent myeloid lineage devel-
opment (Fig 6). This includes granulocyte-monocyte progenitors and bipotential erythroid-
megakaryocyte progenitors, with effects on megakaryocyte and erythroid lineage specification
being of particular relevance. In these latter roles, haploinsufficiency of functional Erg resulted
in fewer bipotential erythroid-megakaryocyte progenitors and a propensity toward CFU-E for-
mation, consistent with previous transplantation studies which demonstrated a bias toward
erythroid lineage formation from Erg+/Mld2 HSCs [22]. Trisomy specifically related to Erg in
the Ts(1716)65Dn model led to expansion of bipotential megakaryocyte-erythroid progenitors,
fewer committed erythroid progenitors and megakaryocytosis [20]. This finding is consistent
with changes in human DS foetal livers [15] and other independent murine models of Erg over-
expression [24,40]. Indeed, aberrant megakaryocyte-erythroid differentiation and erythroid
maturation block may be a potential unifying mechanism for Erg in predisposing to acute bipo-
tential megakaryocytic-erythroid leukemia [25]. The selective expansion of CD150+CD9hi cells
within bipotential megakaryocyte-erythroid progenitor compartment in Ts(1716)65Dn mice is
Fig 6. Perturbation of functional Erg gene dosage induces lineage specific gene expression changes
in multipotential progenitor cells. Trisomy of Erg in Ts(1716)65Dnmice and Erg haploinsufficiency inMld2
mutants induce lineage specific gene expression changes in multipotential hematopoietic progenitor cells.
Trisomy of Erg leads to an increase in bipotential erythroid-megakaryocytic progenitors, erythroid maturation
block, megakaryocytosis, and the pre-leukemic human DS foetal liver phenotype. Haploinsufficiency of Erg
results in in fewer bipotential progenitors and an increase in committed erythroid progenitors as observed in
the Erg+/mld2mouse.
doi:10.1371/journal.pgen.1005211.g006
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similar to that observed in murine models of thrombopoietin driven myeloproliferation
[33,34], providing additional evidence that this progenitor population correlates with the de-
gree of megakaryocytosis in disease models. It was also noted that Ts(1716)65Dn mice exhibited
increased numbers of GMP, while human DS foetal livers exhibit reduced numbers of these
progenitors [15]. This discrepancy may by attributable to the comparatively low level of endog-
enous Erg expression in murine models relative to human hematopoietic cells [40]. Indeed, in a
transgenic model of ERG overexpression, reduction in GMP number was observed in murine
foetal livers [40], suggesting the level of gene expression and the hematopoietic stage is impor-
tant in explaining this apparently discordant phenotype.
It is notable that the expansion of the LSK compartment in Ts65Dn/Erg+/+/+ mice, which is
specifically dependent on trisomy of Erg [20], reflects expansion of HSPCs in DS foetal livers
[15], and was associated with downregulation of the LSK gene signature and up-regulation of
progenitor cell-specific gene expression patterns, making trisomic LSKs less "stem cell-like".
This suggests that an excess of Erg favors progenitor specification at the expense of HSC main-
tenance. This finding is in keeping with the increased multi-potential pre-progenitor cell fre-
quency in Ts65Dn/Erg+/+/+ bone marrow [20] and the increased propensity to form "blast-my"
colonies upstream from CFU-GEMM in DS foetal liver [15]. These observations also argue
against increased Erg gene dose inducing a program of self-renewal as a leukemogenic mecha-
nism in the development of DS-AMKL and DS-TMD. Indeed, competitive transplantation as-
says using the Ts1Rhr trisomic murine model of DS, which carries a trisomic segment that
includes the Erg gene, demonstrated fewer competitive repopulating units compared to diso-
mic controls [41]. Nevertheless, the observation that the multipotential PreGMFlt3- progenitor
signature was also upregulated in Ts65Dn/Erg+/+/+ CMPs relative to Ts65Dn/Erg+/+/Mld2 sug-
gests that in trisomy, Erg allows maintenance of multipotential progenitor potential while pro-
moting specific lineage commitment toward megakaryocyte and granulocyte-monocyte
differentiation. This would be in keeping with the increase in numbers of total colonies, partic-
ularly megakaryocyte-containing colonies, observed by in vitro culture experiments.
It remains to be determined whether the consequences of genetic perturbations due to triso-
my and effects specific to ERG trisomy in the context of DS as our data may suggest, could be
amenable to therapeutic targeting in the prevention or treatment of DS-TMD or DS-AMKL in
addition to currently available strategies.
Materials and Methods
Mice
Derivation and genotyping of the ErgMld2 mutant allele has been described [21]. Ts(1716)65Dn
mice (The Jackson Laboratory) were maintained as previously described [20]. All mice were
derived from the first-generation progeny of matings between Erg+/Mld2 and Ts(1716)65Dn
mice and genotyped as previously described [42]. This study was performed in accordance
with the Australian Code for the Care and Use of Animals for Scientific Purposes, published by
the Australian National Health and Medical Research Council. Procedures were approved by
the Walter and Eliza Hall Institute of Medical Research Animal Ethics Committee (Approval
number 2012.003).
Haematology
Single-cell suspensions from bone marrow were prepared in balanced salt solution (0.15 M
NaCl, 4 mM KCl, 2 mM CaCl2, 1 mMMgSO4, 1 mM KH2PO4, 0.8 mM K2HPO4, and 15 mM
N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid supplemented with 2% [vol/vol] bovine
calf serum). Clonal analysis of bone marrow cells (2.5x104) was performed in 1 mL semisolid
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agar cultures of 0.3% agar in Dulbecco/s modified Eagles medium containing 20% newborn
calf serum and stem cell factor; SCF (100 ng/mL), erythropoietin; EPO (2 U/mL), and interleu-
kin-3; IL-3 (10 ng/mL), granulocyte colony stimulating factor; G-CSF (103 U/mL), granulo-
cyte-macrophage colony stimulating factor; GM-CSF (103 U/mL) and/or macrophage colony
stimulating factor; M-CSF (103 U/mL). Cultures were incubated at 37°C for 7 days in a fully
humidified atmosphere of 10% CO2 in air, then fixed, dried onto glass slides, and stained for
acetylcholinesterase, Luxol fast blue, and hematoxylin, and the number and type of colonies
were determined.
Flow cytometry
Staining was performed using rat anti-mouse biotinylated or fluorochrome-conjugated anti-
bodies specific for Ter119 (Ly-76), Gr1 (Ly6G and Ly6C), Mac1 (CD11b), B220 (CD45R),
CD4, CD8, CD41, CD34, CD16/32, Sca1 (Ly6A/E), cKit (CD117) and CD150 (Biolegend) and
IL-7 receptor α (IL7Rα), CD48, CD105, and CD9 (eBioscience). Secondary staining used strep-
tavidin PE-Texas-Red (BD Pharmingen). Cells were analyzed using a LSR Fortessa flow cytom-
eter (Becton Dickinson), or cells were sorted using a FACSAria II (Becton Dickinson) flow
cytometer after antibody staining with lineage depletion.
Statistical analysis
Student's unpaired two-tailed t-tests were used using GraphPad Prism v. 5.0a for Mac Os X
(GraphPad Software), unless otherwise specified.
Microarray expression profiling of murine progenitor cell populations
Bone marrow LSK, CMP, GMP andMEP populations were isolated by FACS from 2–4 mice in-
cluding males and females from each genotype (Ts65Dn/Erg+/+/+, Ts65Dn/Erg+/+/Mld2, Erg+/+
and Erg+/Mld2) at ~ 4 months of age. Total RNA was isolated from 100,000–500,000 cells pooled
from genotype and cell population matched samples using the RNeasy Micro kit (Qiagen). RNA
quality was assessed with the Agilent Bioanalyzer 2100 (Agilent Technologies) by using the Agi-
lent RNA 6000 Nanokit (Agilent Technologies) according to the manufacturer's protocol. Up to
200ng of RNA was labelled with the Total Prep RNA amplification kit (Ambion), and comple-
mentary RNA (1.5 μg) was hybridized to 48 arrays using six Illumina MouseWG-6 V2.0 Ex-
pression BeadChips (Illumina, Inc., San Diego, CA) according to Illumina standard protocols.
The resultant microarray probe level data were analyzed by using the limma software package
Version 3.21.1 [38]. Raw intensities were normalized by using the neqc function, which per-
forms normexp background correction followed by quantile normalization using control probes
[43]. Probes were filtered if not detected in any sample (detection P value< 0.05). Pairwise com-
parisons were made by using linear modeling and empirical Bayes moderated t statistics [36].
Empirical array quality weights were estimated and incorporated into the linear models [44]. Al-
lowance was made for possible correlations between RNA samples drawn from the same pool of
mice [45]. The false discovery rate (FDR) was controlled by using the Benjamini-Hochberg algo-
rithm. Probes with FDR of less than 5% were considered to be differentially expressed. The mi-
croarray data have been deposited to the Array Express database (http://www.ebi.ac.uk/
arrayexpress) with accession number E-MTAB-2574.
RNA-seq expression profiling
Validation of the microarray data was undertaken via RNA-seq. Total RNA was extracted
using the RNeasy Plus minikit (Qiagen) from LSK cells sorted independently from three
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trisomic Ts65Dn/Erg+/+/+ (two male and one female) and Erg+/+ controls (two male and one fe-
male) at ~ 4 months of age. Sequencing was performed on an Illumina Hi-Seq 2500, producing
at least 15.9 million 100bp paired-end reads per sample. Reads were mapped to the mm10
mouse genome (Genome Reference Consortium GRCm38) using the Subread aligner [46].
Read counts were summarised at the gene level by featureCounts [47] using NCBI RefSeq gene
annotation. Differential expression analysis utilised the edgeR [48] and limma software pack-
ages. Genes were filtered as not expressed if they failed to achieve at least 0.5 counts per million
reads in at least 2 of the 6 samples. All Entrez gene IDs without an official symbol were re-
moved from further analysis, as were Y chromosome genes, Xist, and immunoglobulin genes,
leaving 14,551 genes for downstream analysis. Library sizes were normalised using the TMM
method [49]. The voom function of the limma package was used to convert read counts to log2
counts per million with associated precision weights [50]. Differential expression was assessed
using empirical Bayes moderated t-statistics [36]. There was a strong correlation between the
gene sets identified as differentially expressed by microarray (S2 Table) with RNA-seq data in
Ts65Dn/Erg+/+/+ versus Erg+/+ LSK cells (ROAST P value = 0.00795) and of the differentially
expressed genes identified from the microarray comparison, over fifty genes were also identi-
fied as differentially expressed using non-pooled independent samples by RNA-Seq with a
P value of less than 0.05.
Expression profiling of human Down syndrome cells
Affymetrix microarray CEL files containing gene expression profiles of human DS CD34+CD38-
HSCs and multipotential progenitors [31] were obtained from the Paterson Institute for Cancer
Research at the University of Manchester and analysed with the affy (version 1.34) and limma
software packages. Raw intensities were background corrected, normalised and summarized
using the Robust Multiarray Average algorithm. Pairwise comparisons were made by using line-
ar modeling and empirical Bayes moderated t statistics.
Expression signature analyses
Gene sets from the Molecular Signatures Database (Broad Institute, Version 2.5) were mapped
from human to mouse orthologs (http://bioinf.wehi.edu.au/software/MSigDB/). Genuine As-
sociation analysis [37] used the genas function of the limma package. Rotational gene set tests
(ROAST) were performed with the roast function of the limma package, using the “mean” set
statistic, array quality weights, Holm modification for multiple testing and 10000 rotations
[39]. Moderated t-statistics were used to weight genes in the gene set tests. Barcode plots were
made using the barcodeplot function of the limma package.
Heatmaps were plotted using the Heatmap.2 function from the gplots software package,
using Pearson correlation for hierarchical clustering for rows and columns. Gene signatures
were represented in a heatmap as Z score equivalents. The Z scores were derived from the stan-
dard normal distribution and correspond to the continuity-corrected single-tailed P values ob-
tained from the ROAST tests, with a positive Z score for an up-regulated gene set and negative
Z score for a down-regulated gene set.
Supporting Information
S1 Table. Immunophenotypic definitions of bone marrow stem and progenitor cell popula-
tions.
(DOCX)
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S2 Table. Gene expression changes due to full trisomy, attributable specifically to Erg triso-
my, trisomy of non-Erg genes and Erg haploinsufficiency in LSK, CMP, GMP andMEP pro-
genitor populations. Differentially expressed probes using a false discovery rate (FDR) of 0.05
as a consequence of full trisomy (pairwise comparison Ts65Dn/Erg+/+/+ versus Erg+/+), trisomy
of Erg (Ts65Dn/Erg+/+/+ versus Ts65Dn/Erg+/+/Mld2) and non-Erg gene trisomy (Ts65Dn/Erg+/
+/Mld2 versus Erg+/+) in LSK, CMP, GMP and MEP hematopoietic cells (see [20], Fig 1A).
Three biological replicates per cell type per genotype were obtained using pooled RNA derived
from 2–4 mice (including male and female) per genotype per replicate, for a total of 48 arrays.
See also Figs 2, 3, 5 and Table 2.
(XLSX)
S3 Table. Gene signature sets from the curated Broad Institute Molecular Signatures Data-
base version 2.5 (C2MsigDB) compared against gene expression changes in LSKs as a func-
tion of trisomy and trisomy of Erg by rotational gene set testing using ROAST.Upregulated
genes sets are shown with ROAST P-values.
(XLSX)
S4 Table. Signature gene sets of murine hematopoietic stem and progenitor populations.
An expression signature was defined for each cell population by compiling the significantly up-
regulated genes in that cell type compared to the average of all the other populations using a
false discovery rate (FDR) of 0.05. See also Fig 4.
(XLSX)
S5 Table. Transcriptome analysis of Lin-CD34+CD38- hematopoietic stem and primitive
progenitor cells from human DS bone marrow. See also Fig 5.
(XLSX)
S1 Fig. Differential expression of murine orthologs of genes mutated in DS-AMKL: JAK1,
JAK2, JAK3, FLT3, TP53, TRIB1, MPL, EZH2, APC, EXT1 and SMC3, in Ts65DnErg+/+/+
LSK, CMP, GMP and MEP Cells Compared with Erg+/+ Cells.Heatmap diagram of log2 fold
changes of genes expressed in microarray data.
(TIF)
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